• br Conclusions The present protocol for localizing or spotti

  2024-10-26

  

  Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A

• Regardless of the initial treatment

  2024-10-26

  

  Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse

• The chronic induction of skeletal muscle AMPK

  2024-10-26

  

  The chronic induction of skeletal muscle AMPK activity is an attractive therapeutic approach for DMD, as it addresses multiple cellular pathways needed for powerful phenotypic plasticity, including activation of the slow oxidative myofiber program, corrective autophagic signaling, as well as regulat

• The rescue of the behavioral deficit was associated with a

  2024-10-26

  

  The rescue of the behavioral deficit was associated with a significant reduction in the levels of both soluble and insoluble Aβ peptides and their deposition in the atrial natriuretic peptide receptor of the same animals. In search for the mechanism behind the reduced amyloidosis, we assessed APP m

• endothelin receptor Cells have developed strategies aiming t

  2024-10-26

  

  Cells have developed strategies aiming to enhance both the efficiency of proteins with chaperone activity as well as their overall antioxidant capacity to maintain proteostasis under oxidative stress conditions (Miyata et al., 2012). For instance, 2-Cys peroxiredoxin is an abundantly expressed, anti

• Our second patient years old male

  2024-10-26

  

  Our second patient, 42years old male, a farmer, was all right when he went to sleep, but noticed drooping of eyelids and swallowing difficulty when he woke up. He later developed flaccid weakness of all four limbs and was quadriplegic when he was wheeled into the emergency room. He was tachypneic an

• br COX and LOX in post mortem AD brain

  2024-10-26

  

  COX and 5-LOX in post-mortem AD brain Minghetti (2004) reviewed the findings on COX-2 mRNA levels in AD brains, pointing out that the available evidence demonstrated either decreased or increased levels, possibly because of the short half-life of COX-2 transcripts or individual variability. Histo

• The obtained results indicate that even when the impairment

  2024-10-26

  

  The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate

• br Conclusion br Acknowledgement This study was

  2024-10-25

  

  Conclusion Acknowledgement This study was supported by NIH/NINDSR01 NS036812-16. Introduction Stroke is the leading cause of disability and the fifth leading cause of death in the United States (Writing Group et al., 2016). On average, every 4 min a human dies of stroke (Lackland et al., 2

• Amidepsine A receptor br Acknowledgments This work was suppo

  2024-10-25

  

  Acknowledgments This work was supported by the Swiss National Science Foundation. 15-Lipoxygenase 1 (15-LOX-1) is a nonheme, iron-containing enzyme predominantly expressed in reticulocytes, eosinophils, macrophages, mast cells, and bronchial epithelial cells . 15-LOX-1 is a key enzyme involved

• Protein phosphorylation is an important posttranslational me

  2024-10-25

  

  Protein phosphorylation is an important posttranslational mechanism for the regulation of distribution, trafficking, and function of modified proteins (Wang et al., 2014). GluA1 phosphorylation at S845 also has functional consequences (Lu and Roche, 2012). For instance, S845 phosphorylation drove tr

• VEGFR inhibition using sunitinib does not result in tumor gr

  2024-10-25

  

  VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons

• br Experimental Procedures br Acknowledgments

  2024-10-25

  

  Experimental Procedures Acknowledgments We thank the members of the Qing laboratory for helpful suggestions and Biotree Biotech Co., Ltd. (Shanghai, China) for metabolomics analysis and data interpretation. This study was supported by the National Key Research and Development Program of China

• br Conclusion br Introduction The identification of

  2024-10-25

  

  Conclusion Introduction The identification of Alzheimer's disease (AD) biomarkers and their ability to measure pathology antemortem has led to a fundamental reconsideration of the pathogenesis of AD. The importance of biomarkers was already reflected in revised diagnostic criteria proposed by

• AHR is essential for IL production by

  2024-10-25

  

  AHR is essential for IL-22 production by T HATU and ILC3s [83]. Coexpression of AHR and RORγt by retroviral transduction in a thymoma cell line, EL4, synergistically upregulates IL-22 expression [48]. The cooperativity between AHR and RORγt has also been observed in primary T cells (L.Z., unpublish

8541 records 103/570 page Previous Next First page 上5页 101102103104105 下5页 Last page